Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Summary

This is a Prospective, open, single arm study to evaluate the efficacy and safety of the almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with EGFR mutation

Timeline

Start

2021-06-02

Primary completion

2022-06-02

Completion

2023-06-02

Drugs

Indications